Evidence map›Paper›PMID 31767012›Full record

ArticleBMC medicine2019

Determinants of linear growth faltering among children with moderate-to-severe diarrhea in the Global Enteric Multicenter Study.

Rebecca L Brander, Patricia B Pavlinac, Judd L Walson, Grace C John-Stewart, Marcia R Weaver, Abu S G Faruque, Anita K M Zaidi, Dipika Sur, Samba O Sow, M Jahangir Hossain and 6 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in BMC medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05519254 (Lactoferrin and Lysozyme Supplementation for Long-term Diarrhea Sequelae), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05519254 phase3recruitingnot on this mapstarted 2023, after this paper: background citation

Lactoferrin and Lysozyme Supplementation for Long-term Diarrhea Sequelae

TypeinterventionalSponsorUniversity of WashingtonRan2023 to 2026Enrolled600ConditionsDiarrhea, Wasting, Malnutrition, ChildArmsLactoferrin, Lysozyme, Lactoferrin + Lysozyme, Placebo
3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Association between chlorine-treated drinking water, the gut microbiome, and enteric pathogen burden in young children in Haiti: An observational study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Observational
  10. Article
  11. Article
  12. Article
  13. Reassessing potential economic value and health impact of effectiveBulletin of the World Health Organization · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Moderate-to-Severe Diarrhea and Stunting Among Children Younger Than 5 Years: Findings From the Vaccine Impact on Diarrhea in Africa (VIDA) Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rebecca L BranderDepartment of Epidemiology, University of Washington, Seattle, WA, USA. rbrander@uw.edu.
Patricia B PavlinacDepartment of Global Health, University of Washington, Seattle, WA, USA.
Judd L WalsonDepartment of Epidemiology, Global Health, Pediatrics, Medicine, Childhood Acute Illness and Nutrition Network, University of Washington, Seattle, WA, USA.
Grace C John-StewartDepartment of Epidemiology, Global Health, Pediatrics, Medicine, University of Washington, Seattle, WA, USA.
Marcia R WeaverDepartment of Global Health, Health Services, Health Metrics Sciences, University of Washington, Seattle, WA, USA.
Abu S G FaruqueInternational Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh.
Anita K M ZaidiDepartment of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
Dipika SurNational Institute of Cholera and Enteric Diseases, Kolkata, India.
Samba O SowCentre pour le Développement des Vaccines, Bamako, Mali.
M Jahangir HossainMedical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Pedro L AlonsoCentro de Investigação em Saúde da Manhiça, Maputo, Mozambique.
Robert F BreimanGlobal Disease Detection Division, Kenya Office of the US Centers for Disease Control and Prevention, Nairobi, Kenya.
Dilruba NasrinCenter for Vaccine Development, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
James P NataroCenter for Vaccine Development, Department of Medicine, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
Myron M LevineCenter for Vaccine Development and Global Health, Department of Pediatrics and Medicine, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
Karen L KotloffCenter for Vaccine Development and Global Health, Department of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.

Funding

Addressing adverse outcomes following acute illness among children in Sub-Saharan Africa: predicting risks and cost-effectivenessF31HD096776 · NICHD · UNIVERSITY OF WASHINGTON · PI BRANDER, REBECCA · 2018 to 2018
$43k
NICHD NIH HHS F31 HD096776
6 · The paper itself

Abstract

backgroundModerate-to-severe diarrhea (MSD) in the first 2 years of life can impair linear growth. We sought to determine risk factors for linear growth faltering and to build a clinical prediction tool to identify children most likely to experience growth faltering following an episode of MSD.

methodsUsing data from the Global Enteric Multicenter Study of children 0-23 months old presenting with MSD in Africa and Asia, we performed log-binomial regression to determine clinical and sociodemographic factors associated with severe linear growth faltering (loss of ≥ 0.5 length-for-age z-score [LAZ]). Linear regression was used to estimate associations with ΔLAZ. A clinical prediction tool was developed using backward elimination of potential variables, and Akaike Information Criterion to select the best fit model.

resultsOf the 5902 included children, mean age was 10 months and 43.2% were female. Over the 50-90-day follow-up period, 24.2% of children had severe linear growth faltering and the mean ΔLAZ over follow-up was - 0.17 (standard deviation [SD] 0.54). After adjustment for age, baseline LAZ, and site, several factors were associated with decline in LAZ: young age, acute malnutrition, hospitalization at presentation, non-dysenteric diarrhea, unimproved sanitation, lower wealth, fever, co-morbidity, or an IMCI danger sign. Compared to children 12-23 months old, those 0-6 months were more likely to experience severe linear growth faltering (adjusted prevalence ratio [aPR] 1.97 [95% CI 1.70, 2.28]), as were children 6-12 months of age (aPR 1.72 [95% CI 1.51, 1.95]). A prediction model that included age, wasting, stunting, presentation with fever, and presentation with an IMCI danger sign had an area under the ROC (AUC) of 0.67 (95% CI 0.64, 0.69). Risk scores ranged from 0 to 37, and a cut-off of 21 maximized sensitivity (60.7%) and specificity (63.5%).

conclusionYounger age, acute malnutrition, MSD severity, and sociodemographic factors were associated with short-term linear growth deterioration following MSD. Data routinely obtained at MSD may be useful to predict children at risk for growth deterioration who would benefit from interventions.

Indexed as

AfricaAsiaDiarrhea, InfantileFemaleGrowth DisordersHumansInfantInfant, NewbornMalePrevalenceRisk FactorsClinical predictionDiarrheal diseasesDiarrhea sequelaeGrowth retardationMalnutritionNutritional deteriorationStunting

Identifiers

PMID31767012
PMCPMC6878715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.